A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)

NCT01636960 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
9
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated after 118 weeks from the study start, during the maintenance phase, due to regulatory approval in Japan.

Conditions

Interventions

Sponsor

Merck Sharp & Dohme LLC